| [1] |
Stern JS, Burza S, Robertson MM. Gilles de la Tourette's syndrome and its impact in the UK[J]. Postgrad Med J, 2005, 81(951): 12–19.
|
| [2] |
Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part Ⅱ：pharmacological treatment[J]. Eur Child Adolesc Psychiatry, 2011, 20(4): 173–196.
|
| [3] |
Cavanna AE, Seri S. Tourette's syndrome[J]. BMJ, 2013, 347: f4964.
|
| [4] |
Robertson MM, Eapen V, Cavanna AE. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective[J]. J Psychosom Res, 2009, 67(6): 475–483.
|
| [5] |
Sullivan S, Rai D, Golding J, et al. The association between autism spectrum disorder and psychotic experiences in the Avon longitudinal study of parents and children (ALSPAC) birth cohort[J]. J Am Acad Child Adolesc Psychiatry, 2013, 52(8): 806–814.e2.
|
| [6] |
Knight T, Steeves T, Day L, et al. Prevalence of tic disorders: a systematic review and meta-analysis[J]. Pediatr Neurol, 2012, 47(2): 77–90.
|
| [7] |
Felling RJ, Singer HS. Neurobiology of Tourette syndrome: current status and need for further investigation[J]. J Neurosci, 2011, 31(35): 12387–12395.
|
| [8] |
Robertson MM, Stern JS. Gilles de la Tourette syndrome: symptomatic treatment based on evidence[J]. Eur Child Adolesc Psychiatry, 2000, 9(Suppl 1): I60–I75.
|
| [9] |
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies[J]. Am J Psychiatry, 2004, 161(3): 414–425.
|
| [10] |
Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review[J]. J Psychopharmacol, 2005, 19(5): 533–550.
|
| [11] |
Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome[J]. J Neurol Neurosurg Psychiatry, 2010, 81(1): 70–73.
|
| [12] |
Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed[J]. Epilepsia, 2000，41(11): 1364–1374.
|
| [13] |
Pandey S, Rathore C, Michael BD. Antiepileptic drugs for the primary and secondary prevention of seizures in viral encephalitis[J]. Cochrane Database Syst Rev, 2014, 10: CD010247.
|
| [14] |
Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews[J]. Cochrane Database Syst Rev, 2013, 11: CD010567.
|
| [15] |
Awaad Y, Michon AM, Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome[J]. Mov Disord, 2005, 20(6): 714–718.
|
| [16] |
Fernández-Jaén A, Fernández-Mayoralas DM, Muoz-Jareo N, et al. An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome[J]. Eur J Paediatr Neurol, 2009, 13(6): 541–545.
|
| [17] |
Poulain P, Margineanu DG. Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones[J]. Neuropharmacology，2002，42(3): 346–352.
|
| [18] |
Rigo JM, Hans G, Nguyen L，et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents[J]. Br J Pharmacol, 2002, 136(5): 659–672.
|
| [19] |
Toth M. The epsilon theory: a novel synthesis of the underlying molecular and electrophysiological mechanisms of primary generalized epilepsy and the possible mechanism of action of valproate[J]. Med Hypotheses, 2005, 64(2): 267–272.
|
| [20] |
Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial[J]. Neurology, 2006, 66(5): 672–677.
|
| [21] |
Abuzzahab FS, Brown VL. Control of Tourette's syndrome with topiramate[J]. Am J Psychiatry, 2001, 158(6): 968.
|
| [22] |
Kuo SH, Jimenez-Shahed J. Topiramate in treatment of tourette syndrome[J]. Clin Neuropharmacol, 2010, 33(1): 32–34.
|
| [23] |
Yang CS, Zhang LL, Zeng LN, et al. Topiramate for Tourette's syndrome in children: a meta-analysis[J]. Pediatr Neurol, 2013, 49(5): 344–350.
|
| [24] |
Awaad Y, Michon AM, Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome[J]. Mov Disord, 2005, 20(6): 714–718.
|
| [25] |
Fernández-Jaén A, Fernández-Mayoralas DM, Muoz-Jareo N, et al. An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome[J]. Eur J Paediatr Neurol, 2009, 13(6): 541–545.
|
| [26] |
Smith-Hicks CL, Bridges DD, Paynter NP, et al. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome[J]. Mov Disord, 2007, 22(12): 1764–1770.
|
| [27] |
Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome[J]. Pediatr Neurol, 2009, 40(6): 420–425.
|
| [28] |
Ye L, Lippmann S. Tourette disorder treated with valproic acid[J]. Clin Neuropharmacol, 2014, 37(1): 36–37.
|
| [29] |
Yang CS, Zhang LL, Lin YZ, et al. Sodium valproate for the treatment of Tourette's syndrome in children: a systematic review and meta-analysis[J]. Psychiatry Res, 2015, 226(2-3): 411–417.
|
| [30] |
Swain JE, Leckman JF. Tourette's syndrome in children[J]. Curr Treat Options Neurol, 2003, 5(4): 299–308.
|
| [31] |
Goetz CG. Clonidine and clonazepam in Tourette syndrome[J]. Adv Neurol, 1992, 58: 245–251.
|
| [32] |
Cavanna AE, Nani A. Antiepileptic drugs and Tourette syndrome[J]. Int Rev Neurobiol, 2013, 112: 373–389.
|
| [33] |
Gonce M, Barbeau A. Seven cases of Gilles de la Tourette's syndrome: partial relief with clonazepam: a pilot study[J]. Can J Neurol Sci, 1977, 4(4): 279–283.
|
| [34] |
Steingard RJ, Goldberg M, Lee D, et al. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD[J]. J Am Acad Child Adolesc Psychiatry, 1994, 33(3): 394–399.
|
| [35] |
Lee HW, Jung DK, Suh CK, et al. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up[J]. Epilepsy Behav, 2006, 8(4): 736–741.
|
| [36] |
Eddy CM, Rickards HE, Cavanna AE. Behavioral adverse effects of antiepileptic drugs in epilepsy[J]. J Clin Psychopharmacol, 2012, 32(3): 362–375.
|
| [37] |
Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder[J]. Neuropsychiatr Dis Treat, 2006, 2(4): 475–488.
|
| [38] |
Gomer B, Wagner K, Frings L, et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate[J]. Epilepsy Behav, 2007, 10(3): 486–494.
|
| [39] |
Huang CW, Pai MC, Tsai JJ. Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy[J]. Psychiatry Clin Neurosci, 2008, 62(5): 548–553.
|
| [40] |
Levisohn PM, Mintz M, Hunter SJ, et al. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial[J]. Epilepsia, 2009, 50(11): 2377–2389.
|
| [41] |
Piazzini A, Chifari R, Canevini MP, et al. Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy[J]. Epilepsy Res, 2006, 68(3): 181–188.
|
| [42] |
Piedad J, Rickards H, Besag FM, et al. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations[J]. CNS Drugs, 2012, 26(4): 319–335.
|